Explore pharmaceutical companies to know 2026 delivering innovative pharmacy solutions and improving patient care across the U.S.

Evotec stock remains a speculative "Buy" with a $9/share price target. Here's what investors need to know about EVO.

METI & TSE select Chugai for the “2026 KENKO Investment for Health” for the third consecutive year: Tokyo Tuesday, March 10, 2026, 15:00 Hrs [IST] Chugai Pharmaceutical Co., L ...

Sell on Novo Nordisk A/S: slowing growth, downgraded 2025 guidance, rising GLP-1 competition, pricing/patent risks, limited ...

Research has shown that financial conflicts of interest (COIs) are a common issue in medicine and psychiatry, with a 2020 ...

FRANKFURT, March 10 (Reuters) - The cofounders of BioNTech, Ugur Sahin and Oezlem Tuereci, will leave the COVID-19 vaccine ...

Considering the good news, is Vertex heading to $600? Let's find out.

Irish Pharmaceutical Healthcare Association president Shane Ryan is confident a new accord with Government can deliver for ...

Watch scenes from the performances nominated for best actress at the 98th annual Academy Awards, as well as interviews with ...

Vertex Pharmaceuticals shares surged Tuesday after the company posted promising results from a clinical trial of a drug to treat kidney disease.

Government and private capital should strengthen cooperation with such funds to support innovative drug development and ...

Former politicians involved in such advocacy can exploit vast experience of how Government and politics operate ...